Trading Report: The Analysts gives Consensus Recommendation of “Strong Buy” to Zacks: Alimera Sciences Inc. (ALIM)

The Analysts gives Consensus Recommendation of “Strong Buy” to Zacks: Alimera Sciences Inc. (ALIM)

Shares of Alimera Sciences Inc. (NASDAQ:ALIM) have earned an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation. Alimera Sciences’ rating score has improved by 66.7% from 90 days ago as a result of various analysts’ ratings changes.

Brokers have set a 1-year consensus target price of $3.00 for the company and are predicting that the company will post ($0.05) earnings per share for the current quarter, according to Zacks. Zacks has also given Alimera Sciences an industry rank of 75 out of 265 based on the ratings given to related companies.

A number of equities research analysts have commented on the stock. Zacks Investment Research lowered shares of Alimera Sciences from a “hold” rating to a “sell” rating in a report on Monday, November 21st. Cowen and Company raised shares of Alimera Sciences from a “market perform” rating to an “outperform” rating and set a $3.00 price objective on the stock in a report on Friday, September 16th.

Shares of Alimera Sciences (NASDAQ:ALIM) opened at 1.16 on Friday. Alimera Sciences has a 12-month low of $1.01 and a 12-month high of $5.15. The stock’s 50 day moving average is $1.27 and its 200-day moving average is $1.47. The firm’s market cap is $75.24 million.

Alimera Sciences (NASDAQ:ALIM) last issued its quarterly earnings data on Wednesday, November 2nd. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by $0.05. The business had revenue of $8.30 million for the quarter, compared to analysts’ expectations of $10.53 million. During the same quarter in the prior year, the company posted ($0.21) earnings per share. The firm’s revenue was up 20.3% on a year-over-year basis. On average, analysts anticipate that Alimera Sciences will post ($0.54) EPS for the current fiscal year.

In other news, insider Richard S. Eiswirth, Jr. sold 51,471 shares of the firm’s stock in a transaction dated Thursday, September 15th. The shares were sold at an average price of $1.51, for a total value of $77,721.21. Following the transaction, the insider now owns 86,445 shares of the company’s stock, valued at approximately $130,531.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 14.00% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of ALIM. PNC Financial Services Group Inc. raised its position in Alimera Sciences by 107.3% in the third quarter. PNC Financial Services Group Inc. now owns 95,100 shares of the biopharmaceutical company’s stock valued at $142,000 after buying an additional 49,215 shares during the last quarter. Northern Trust Corp raised its position in Alimera Sciences by 108.9% in the third quarter. Northern Trust Corp now owns 105,320 shares of the biopharmaceutical company’s stock valued at $157,000 after buying an additional 54,906 shares during the last quarter. Paloma Partners Management Co purchased a new position in Alimera Sciences during the second quarter valued at $140,000. Spark Investment Management LLC purchased a new position in Alimera Sciences during the third quarter valued at $262,000. Finally, Sphera Funds Management LTD. purchased a new position in Alimera Sciences during the third quarter valued at $299,000. 31.80% of the stock is currently owned by institutional investors.

About Alimera Sciences

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

Related posts

Leave a Comment